A5017280138- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer therapeutics and mechanisms
- Pancreatitis Pathology and Treatment
- Cancer Treatment and Pharmacology
- COVID-19 Clinical Research Studies
- Dermatological and COVID-19 studies
Universidade de São Paulo
2021
Oncology Hematology Care
2006-2009
University of Cincinnati
2006
This study aim was to determine the efficacy and safety of combination Gemcitabine 1000mg/m2 day 1 & 8 Irinotecan 100 mg/m2 with escalating dose thalidomide in chemonaive patients advanced non-small cell lung cancer. Among 20 who met eligibility criteria received treatment, two (10%) experienced partial response 14 (70%) stable disease. The median time disease progression 4 months (95% CI: 2.8–6.6). year 2 survival rates were 36% 27%, respectively. is active NSCLC manageable toxicity profile.
Abstract The development of new approaches that allow early assessment which cases COVID-19 will likely become critical and the discovery therapeutic targets are urgent demands. In this cohort study, we performed proteomic laboratorial profiling plasma from 163 patients admitted to Bauru State Hospital (Bauru, SP, Brazil) between May 4 th July , 2020, who were diagnosed with by RT-PCR nasopharyngeal swab samples. Plasma samples collected upon admission for routine laboratory analyses shotgun...
17068 Background: Chemotherapy with platinum based doublets provides only a modest benefit in advanced NSCLC median overall survival (OS) of 8 months and 1-year rate 33% (Schiller JH et al, N Engl J Med 2002). We performed phase II study to determine the efficacy thalidomide, an immunomodulatory agent antiangiogenic activity, combination chemotherapy patients NSCLC. Methods: Chemonaive stage IIIB/IV ECOG PS≤ 2 adequate organ function were treated G (1000 mg/m ) I (100 IV on days 1 21 day...